

The cancer challenge: how to create a win- win solution

ECPC Annual Congress, Bruxelles, 8-9 June 2018

Ivana Cattaneo, Vice-Chair of the EFPIA Oncology Platform, Director Public Affairs Oncology Europe, Novartis

European Federation of Pharmaceutical Industries and Associations

¹ www.efpia.eu



EFPIA Oncology Platform committed to work towards fast and equal access to cancer medicines

- * Access to innovation:

- * Large differences in access to cancer medicines across Europe
- * Access delays are further emphasized by the increasing strain on public finances and growing disparities across Europe (West v. East) and within countries

- * Industry vision for cancer care:

- * Recognizing these challenges and the need to intervene, EFPIA member companies have aligned behind key guiding principles underpinning industry's commitment to improve cancer care and patient outcomes e.g. by increasing life years saved
- * There is consensus on the need to restore trust and dialogue with key stakeholders and understand their priorities to devise a mutually beneficial commitment plan



Addressing access challenges requires a dialogue between all stakeholders

- * Care and resource prioritization
 - * Slow adaptability of healthcare systems to the speed of evolution in cancer treatment e.g. combination therapy, personalized medicines, immuno-therapy
 - * Funding constraints as a result of economic downturn and growing disease burden due to demographics – deeper budget deficits and mismatch between the rising burden of the disease and the roughly flat spend on care
 - * Inconsistencies in prioritization of healthcare and cancer care on the public policy agenda across Europe despite the prevailing disease burden and amplitude of future challenges
- * Access to innovation
 - * Disconnect between regulatory and HTA/ pricing & reimbursement procedures resulting in delayed/ denied access
 - * Restrictive value assessment frameworks i.e. reluctance to use RWD/ surrogate endpoints, inadequate assessment of socio-economic impact
 - * Limited flexibility for access agreements between and within countries resulting in uneven or delayed access
 - * Growing disparities in care delivery and outcomes within and across countries

Making The Vision A Reality – Industry Proposals: The What



- * **Value:** Secure appropriate valuation of innovation in cancer therapies
 - * Adapt processes / frameworks to better reflect a progressive perspective on value
 - * Definition of standard and meaningful use of RWD
 - * Consider patient perspective going beyond cost-utility, and greater consistency in evidence requirements between Regulatory, HTA and P&R agencies.
- * **Resourcing:** Ensure sufficient payer resource allocation to cancer care
 - * Increase in absolute funding levels for cancer
 - * Effective and up to date cancer plans in place
 - * Improved horizon scanning
- * **Affordability:** Encourage payers to implement innovative and timely reimbursement approaches
 - * Development of more flexible P&R approaches
 - * Investment in data and administrative infrastructure
 - * Mitigate ERP impact

Collaboration is key for fast and equal patients access




Making The Vision A Reality – Industry Proposals: The How

- * **Learning from science:** complex issues require a systematic and coordinated approach, leveraging different expertizes
- * **Working on area of common interests:** with patients in mind, work on interests instead of positions
- * **Foster a multistakeholder format to find solution:** Win⁴
Patients, Physicians, Payors and (HC) Providers

Challenges of today can only be overcome by acting together

EFPIA Cancer Initiative Involved Over 150 Stakeholders In More Than 10 Countries





Taking action on cancer together: delivering the future of cancer care in Europe

- * Accellerating the time it takes to get new treatments to patients
 - * Assess options to improve participation in clinical trials within the Eu
 - * Develop a model process for accelerating time to access from regulatory to reimbursement
 - * Measure performance across countries (level of access, quality of coverage, delays)
- * Developing tailored pricing and reimbursement models for cancer medicines
 - * Develop a consensus framework for access agreement leveraging data infrastructure
 - * Discuss challenges, opportunities and solution for combination treatments
 - * Work together to advocate the benefits of differential pricing across Europe
- * Improving the sustainability and integration of cancer care
 - * Develop a good practice guide for resource allocation in cancer care
 - * Produce an analysis of best practices in cancer service across Europe against the backdrop of National Cancer Control Plans to optimize patient outcomes
 - * Map initiatives to improve data collection and usage, share experiences of successes and blockages, propose solutions to accelerate progress
 - * Develop a shared vision for cancer care that delivers best outcomes for patients

In conclusion



Call to action

Participants in the discussions agreed on a shared ambition:

"To work further together to achieve consistent high standards in patient outcomes for cancer across the whole of Europe"

In our commitment to this and the priorities above, we have identified a number of ideas where collaborative action could make a difference. These suggestions are set out below – some of which are already being implemented – with an explanation of how they could translate into practical solutions to ensure a better future for cancer patients in Europe.



efpia

EFPIA Brussels Office

Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels - Belgium
Tel: +32 (0)2 626 25 55

www.efpia.eu